Parnetti Lucilla, Cicognola Claudia, Eusebi Paolo, Chiasserini Davide
Section of Neurology, Department of Medicine, Center for Memory Disturbances, University of Perugia, Sant' Andrea delle Fratte, 06132 Perugia, Italy.
Clinical Neurochemistry Laboratory, Department of Psychiatry & Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Biomark Med. 2016;10(1):35-49. doi: 10.2217/bmm.15.107. Epub 2015 Dec 8.
Since diagnosis of Parkinson's disease (PD) is mostly based on clinical criteria, it is almost impossible to formulate an early diagnosis, as well as a timely differential diagnosis versus other parkinsonisms. A great effort in searching reliable biomarkers both for early diagnosis and prognosis in PD is currently ongoing. Cerebrospinal fluid has been widely investigated as potential source for such biomarkers, with particular emphasis on α-synuclein (α-syn) species. We reviewed all the clinical studies carried out so far on cerebrospinal fluid quantification of α-syn species in PD. Current evidence supports the value of total and oligomeric α-syn in PD diagnosis and in the differential diagnosis of PD and other parkinsonisms. Conversely, the role of α-syn species in PD prognosis remains unsatisfactory.
由于帕金森病（PD）的诊断主要基于临床标准，因此几乎不可能进行早期诊断，也难以与其他帕金森症进行及时的鉴别诊断。目前正在大力寻找可靠的生物标志物用于PD的早期诊断和预后评估。脑脊液已被广泛研究作为此类生物标志物的潜在来源，尤其关注α-突触核蛋白（α-syn）。我们回顾了迄今为止所有关于PD患者脑脊液中α-syn定量的临床研究。目前的证据支持总α-syn和寡聚α-syn在PD诊断以及PD与其他帕金森症鉴别诊断中的价值。相反，α-syn在PD预后中的作用仍不明确。
